Sign Up
Stories
Aldeyra Therapeutics R&D Day 2024
Share
4D Molecular Therapeutics Raises $300 Mi...
ABIONYX Pharma Files 2023 Document
ACTICOR BIOTECH: Financial Report Postpo...
AI-Powered Antigen Research Partnership
BioNTech's mRNA Cancer Vaccine Progress
Breakthrough Animal Study for EVX-B1 Vac...
Overview
API
Aldeyra Therapeutics will conduct a Research & Development Day in April 2024, showcasing pipeline programs for immune-mediated and metabolic diseases. The event will spotlight RASP modulators ADX‑629, ADX‑246, and ADX‑248, aiming to enhance pathways and lower toxicity.
Ask a question
How could the outcomes of the R&D Day influence Aldeyra Therapeutics' market position and partnerships?
How might the development of RASP modulators impact the treatment landscape for immune-mediated diseases?
What potential challenges could Aldeyra Therapeutics face in optimizing protein systems with their pharmaceuticals?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage